This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: laropiprant

In brief – cardiology news roundup

March 2013 Br J Cardiol 2013;20:16-17

In brief – cardiology news roundup

BJCardio Staff

Abstract

New editorial board member Dr Ketan Dhatariya We are delighted to welcome Dr Ketan Dhatariya to our editorial board. Dr Dhatariya is a consultant in diabetes, endocrinology and general medicine at Norfolk and Norwich University Hospital, Norwich. He is also a senior lecturer at the University of East Anglia, and an assistant professor of medicine at St George’s University, Grenada, in the West Indies. He has published on a wide variety of diabetes- and endocrine-related subjects, including diabetes-related foot disease. He serves as meetings secretary for the Association of British Clinical Diabetologists, and medical secretary for the Spec

| Full text

September 2009 Br J Cardiol 2009;16:226

In brief

BJCardio editorial staff

Abstract

Nicotinic acid/laropiprant combination launched in UK A combination of nicotinic acid and laropiprant (Tredaptive®), for the treatment of dyslipidaemia (particularly combined mixed dyslipidaemia and primary hypercholesterolaemia) has been launched in the UK by Merck Sharp & Dohme. It should be used in combination with statins when the cholesterol-lowering effect of statin monotherapy is inadequate, and as monotherapy only if statins are thought inappropriate or if they are not tolerated. Diet and other non-pharmacological measures to control lipid levels should be continued. It is hoped that the addition of the anti-flushing agent laropi

| Full text

March 2009 Br J Cardiol 2009;16:90–7

Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia

Gilbert Gleim, Christie M Ballantyne, Nancy Liu, Sally Thompson-Bell, Christine McCrary Sisk, Richard C Pasternak, Yale Mitchel, John F Paolini

Abstract

Introduction Large intervention studies suggest that while lowering low-density lipoprotein cholesterol (LDL-C) is beneficial, it is insufficient to prevent the majority of coronary heart disease (CHD) events. Niacin improves the overall lipid profile, LDL-C and triglycerides (TG) and is the most effective agent for raising high-density lipoprotein cholesterol (HDL-C) levels.1 Co-administration of niacin with a statin offers the potential for additional lipid management, but the use of niacin has been limited due to associated flushing, mediated primarily by prostaglandin D2 (PGD2).2 Flushing of the face and trunk occurs in nearly all patient

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now